GlassScriptPhysician profile
Sadaf Ausaf
NPI 1548573439
$1,102.13
in general payments reported to CMS, 2019-2025
14 companies · $895 in 2025
The $895 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $154 · 2024: $53.12 · 2025: $895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,102.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $276.14 | 2023-2025 | Dalvance, Teflaro |
| Astrazeneca Pharmaceuticals LP | $155.00 | 2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $139.13 | 2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $100.47 | 2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.03 | 2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.52 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $50.51 | 2025 | |
| Dexcom, INC. | $50.34 | 2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $48.65 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.47 | 2025 | Xifaxan |
| Ferring Pharmaceuticals INC. | $27.22 | 2025 | Rebyota |
| Eisai INC. | $20.13 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.41 | 2025 | Trintellix |
| Pfizer INC. | $19.11 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sadaf Ausaf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.